Recombinant multi-species MLN protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine MLN protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a small peptide hormone that is secreted by cells of the small intestine to regulate gastrointestinal contractions and motility. Proteolytic processing of the secreted protein produces the mature peptide and a byproduct referred to as motilin-associated peptide (MAP). Three transcript variants encoding different preproprotein isoforms but the same mature peptide have been found for this gene. [provided by RefSeq, May 2010]
The Alternative Names of target: MLN,Mln,Promotilin

Target products collectionGo to MLN products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-SE0351-Ag-1/ GM-Tg-hg-SE0351-Ag-2 Human MLN protein Human
GM-Tg-rg-SE0351-Ag-1/ GM-Tg-rg-SE0351-Ag-2 Rat MLN protein Rat
GM-Tg-mg-SE0351-Ag-1/ GM-Tg-mg-SE0351-Ag-2 Mouse MLN protein Mouse
GM-Tg-cynog-SE0351-Ag-1/ GM-Tg-cynog-SE0351-Ag-2 Cynomolgus/Rhesus macaque MLN protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-SE0351-Ag-1/ GM-Tg-felg-SE0351-Ag-2 Feline MLN protein Feline
GM-Tg-cang-SE0351-Ag-1/ GM-Tg-cang-SE0351-Ag-2 Canine MLN protein Canine
GM-Tg-bovg-SE0351-Ag-1/ GM-Tg-bovg-SE0351-Ag-2 Bovine MLN protein Bovine
GM-Tg-equg-SE0351-Ag-1/ GM-Tg-equg-SE0351-Ag-2 Equine MLN protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-SE0351-Ag-1/ GM-Tg-hg-SE0351-Ag-2; GM-Tg-rg-SE0351-Ag-1/ GM-Tg-rg-SE0351-Ag-2;
GM-Tg-mg-SE0351-Ag-1/ GM-Tg-mg-SE0351-Ag-2; GM-Tg-cynog-SE0351-Ag-1/ GM-Tg-cynog-SE0351-Ag-2;
GM-Tg-felg-SE0351-Ag-1/ GM-Tg-felg-SE0351-Ag-2; GM-Tg-cang-SE0351-Ag-1/ GM-Tg-cang-SE0351-Ag-2;
GM-Tg-bovg-SE0351-Ag-1/ GM-Tg-bovg-SE0351-Ag-2; GM-Tg-equg-SE0351-Ag-1/ GM-Tg-equg-SE0351-Ag-2
Products Name MLN protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name MLN
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine MLN protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.